Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
2024 · Nature Medicine · 53 citations
https://doi.org/10.1038/s41591-024-03249-3
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
154
Citations
4
h-index
2
i10-index
R. Gielen is an academic researcher from The Netherlands Cancer Institute. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Schizophrenia research and treatment & Bipolar Disorder and Treatment. The author has an h-index of 4, co-authored 8 publications.
Click to start Chat